Q-omics provides the consensus-scored MAPK10-AS1 profile across patient tissues and cancer cell-line models. MAPK10-AS1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, MAPK10-AS1 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, MAPK10-AS1 RNA expression shows 16,808 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight CHOL, BLCA, and LUAD as cancer lineages where MAPK10-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAPK10-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAPK10-AS1 survival associations across molecular data types. MAPK10-AS1 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAPK10-AS1 RNA expression–survival associations across cancer types. High MAPK10-AS1 expression shows unfavorable associations in CHOL, THCA, LIHC, SKCM and MESO, but favorable associations in DLBC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify CHOL as the clearest survival context for MAPK10-AS1 RNA expression.
This table summarizes MAPK10-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAPK10-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAPK10-AS1 shows lower tumor expression in BLCA, THCA and ESCA and higher tumor expression in LUSC. The BLCA box plot shows higher MAPK10-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.177, t-test p = .004).
This table shows molecular features associated with MAPK10-AS1 in patient tissues and cancer cell lines. In patient samples, MAPK10-AS1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
